Polatuzumab vedotin (Polivy®). HTA ID: 22043

Assessment Status NCPE Assessment Process Complete
HTA ID 22043
Drug Polatuzumab vedotin
Brand Polivy®
Indication In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Assessment Process
Rapid review commissioned 27/06/2022
Rapid review completed 27/07/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pola-R-CHP compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/08/2022
Pre-submission consultation with Applicant 08/11/2022
Full submission received from Applicant 26/01/2023
Preliminary review sent to Applicant 20/07/2023
NCPE assessment re-commenced 18/08/2023
Factual accuracy sent to Applicant 16/11/2023
NCPE assessment re-commenced 23/11/2023
NCPE assessment completed 05/12/2023
NCPE assessment outcome The NCPE recommends that polatuzumab vedotin (Polivy®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified
in the Health (Pricing and Supply of Medical Goods) Act 2013.